Erlotinib Terminated Phase 2 / 3 Trials for Squamous Cell Carcinoma (SCC) / Head and Neck Carcinoma Treatment

IndicationsStatusPurposePhase
TerminatedTreatment2 / 3
clinicaltrials.gov IdentifierTitleDrugs
NCT01009203Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma
NCT00750555Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer